Preferred Label : Anti-c-Met/MMAE ADC RC108;
NCIt synonyms : Anti-c-met ADC RC108; c-Met-targeted ADC RC108; c-Met-targeted Antibody-drug Conjugate RC108; Anti-c-Met/MMAE Antibody-drug Conjugate RC108; ADC RC108;
NCIt definition : An antibody-drug conjugate (ADC) consisting of an anti-c-Met monoclonal antibody that
is conjugated to monomethyl auristatin E (MMAE), an auristatin derivative and potent
microtubule disrupting agent, with potential antineoplastic activity. Upon administration
of anti-c-Met/MMAE ADC RC108, the monoclonal antibody moiety targets and binds to
the c-Met protein, which is overexpressed in certain tumor types. After internalization
of the agent, the MMAE moiety is released and binds to tubulin and inhibits its polymerization,
which results in G2/M phase arrest and apoptosis. This inhibits the proliferation
of c-Met-expressing tumor cells. c-Met, also known as hepatocyte growth factor receptor
(HGFR), is a receptor tyrosine kinase that is overexpressed or mutated in many tumor
cell types and plays a key role in tumor cell proliferation, survival, invasion, metastasis,
and tumor angiogenesis. Its expression is associated with poor prognosis in many solid
tumor types.;
Molecule name : RC-108; RC 108;
NCI Metathesaurus CUI : CL1661899;
Origin ID : C179288;
UMLS CUI : C5555587;
Semantic type(s)
- concept_is_in_subset
- has_target
